海翔药业(002099) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥804,527,527.52, representing a 25.26% increase compared to ¥642,309,773.93 in the same period last year[3] - Net profit attributable to shareholders was ¥87,024,150.17, up 52.17% from ¥57,187,894.76 year-on-year[3] - Basic earnings per share rose to ¥0.05, a 25.00% increase from ¥0.04 in the same period last year[3] - Net profit for the current period was ¥86,547,687.52, representing a 52.5% increase compared to ¥56,846,105.31 in the same period last year[21] Cash Flow and Operating Activities - The net cash flow from operating activities increased by 21.40% to ¥149,627,750.29, compared to ¥123,247,740.86 in the previous year[3] - Cash flow from operating activities generated ¥149,627,750.29, compared to ¥123,247,740.86 in the previous period, marking a 21.4% increase[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,991,182,946.80, a slight decrease of 0.36% from ¥8,019,943,288.69 at the end of the previous year[4] - Total liabilities decreased to CNY 1.77 billion from CNY 1.91 billion, showing a reduction of approximately 6.9%[17] - The company's equity attributable to shareholders increased to CNY 6.22 billion from CNY 6.12 billion, marking a growth of about 1.8%[17] Investment and Income - The company reported a significant increase in investment income, which rose by 401.24% to ¥5,823,939.13, compared to a loss of ¥1,933,295.84 in the previous year[8] - Other income increased to ¥3,365,583.75 from ¥2,151,254.54, a growth of 56.4%[21] Operating Costs and Expenses - The company's operating costs increased by 48.93% to ¥563,342,170.57, primarily due to increased sales volume and rising unit costs[8] - Total operating costs amounted to ¥707,999,096.02, up 25.8% from ¥562,351,791.33 in the prior period[20] - Research and development expenses decreased to ¥34,757,233.67 from ¥40,190,992.54, a reduction of 13.5%[20] - Sales expenses rose to ¥5,399,712.63, up 33.1% from ¥4,058,842.43 in the previous period[20] - Management expenses decreased significantly to ¥94,783,985.19 from ¥144,335,911.74, a decline of 34.4%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,629, with the largest shareholder holding 32.37% of the shares[9] Cash and Cash Equivalents - Current assets increased slightly to CNY 3.45 billion from CNY 3.44 billion, with cash and cash equivalents at CNY 1.71 billion, down from CNY 1.83 billion[14] - The ending balance of cash and cash equivalents was 1,609,701,019.10 CNY in Q1 2022, compared to 2,150,460,400.33 CNY in Q1 2021[25] Borrowings and Financing Activities - The company received 100,000,000.00 CNY in borrowings during Q1 2022, down from 210,000,000.00 CNY in Q1 2021[25] - The company paid 104,572,083.35 CNY in cash outflows related to financing activities in Q1 2022, compared to 13,844,486.12 CNY in Q1 2021[25] Audit Information - The company did not conduct an audit for the Q1 2022 report[26]